We could demonstrate that a combination of these two factors, both leading to strong NKG2C+ NK cell responses, was completely absent in the EBV+HL and EBV+DLBCL patients of our cohort. The gene discussed is KLRC2; the disease is diffuse large B-cell lymphoma.